US 11661426
Imidazole-containing inhibitors of ALK2 kinase
granted A61PA61P19/00A61P35/00
Quick answer
US patent 11661426 (Imidazole-containing inhibitors of ALK2 kinase) held by BioCryst Pharmaceuticals, Inc. expires Mon May 25 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- BioCryst Pharmaceuticals, Inc.
- Grant date
- Tue May 30 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon May 25 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 42
- CPC classes
- A61P, A61P19/00, A61P35/00